Biogen leaders warn sales teams: Only 2,000 patients might access Aduhelm over the next several years

Biogen execs on Thursday tried to level with their Aduhelm sales staff and prep for a 28-day blitz to convince CMS to reverse or loosen its recent decision to only cover the controversial Alzheimer’s drug in clinical trials.